Carborane PEG Linkers for Targeted Boron Delivery in BNCT
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current boron neutron capture therapy (BNCT) is underutilized due to challenges such as the lack of effective boron carriers, limited neutron sources, high costs, and inadequate treatment planning, leading to slow deployment and variable clinical outcomes, especially for cancers like glioblastoma and melanoma.
Innovation Solution
Development of carborane-based boron enriched linkers (BELs) conjugated to ligands, particularly monoclonal antibodies, to enhance boron concentration in tumors, enabling targeted neutron capture therapy and improved treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional boron carriers are used in BNCT, then the treatment can be administered, but the boron concentration in tumors is insufficient and clinical outcomes are variable
Solution Approach 1:
The patent employs monoclonal antibodies as intermediary carriers that specifically bind to tumor antigens, facilitating targeted delivery of boron compounds to tumor cells. This mediator approach resolves the contradiction by enabling precise tumor targeting while maintaining safety, thereby improving both boron concentration in tumors and clinical outcomes.
Solution Approach 2:
The invention applies local quality by designing boron-containing compounds that are selectively accumulated in tumor tissues through passive or active targeting mechanisms. This localized concentration of boron in tumors, rather than uniform distribution, directly addresses the contradiction between achieving sufficient boron concentration and ensuring reliable clinical outcomes.
2Productivity
If BNCT is deployed in hospitals, then cancer treatment is provided, but the cost is high and deployment is slow
Solution Approach 1:
The patent utilizes readily available monoclonal antibodies and small-molecule boron compounds that can be synthesized at lower cost compared to developing new accelerator systems. By leveraging existing pharmaceutical infrastructure and standardized conjugation chemistry, the invention enables more economical and rapid deployment of BNCT without requiring complex, expensive accelerator technology.
3Ease of operation
If boron is delivered non-specifically in BNCT, then the treatment can be administered, but side effects increase and treatment precision decreases
Solution Approach 1:
The monoclonal antibody serves as a specific intermediary that guides boron delivery to tumor cells while avoiding healthy tissues. This targeted approach maintains ease of administration through simple intravenous injection while dramatically reducing side effects by preventing non-specific boron accumulation in normal organs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of BELs allows for precise delivery of boron to tumors, enhancing the effectiveness of BNCT by increasing boron concentration and reducing side effects, potentially improving treatment outcomes for various cancers and immunological disorders.
Implementation Method 1
conjugated to a ligand, such as a monoclonal antibody, to enhance boron concentration in tumors
Implementation Method 2
boron-10 being present in the tumor at high concentration, and a neutron source that comes in the form of either a research reactor or a particle accelerator
Data Source
AI summary
Boron Enriched Linker (“BEL”) compounds comprising carborane-based boron enriched PEG linkers and methods of making such BELs are disclosed herein. Consequently, the BELs can be conjugated to antibodies or antibody fragments to create Antibody Boron Conjugates (“ABCs”) to provide a method of treating cancer, immunological disorders, and other disease by utilizing a Neutron Capture Therapy modality.